Accordingly, targeting the ROS-TXNIP-NLRP3 pathway has been proposed as a therapeutic opportunity for preventing the progression of NAFLD to NASH in DM [185]. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.